The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,002.00
Bid: 2,006.00
Ask: 2,008.00
Change: -10.00 (-0.50%)
Spread: 2.00 (0.10%)
Open: 2,014.00
High: 2,024.00
Low: 1,994.00
Prev. Close: 2,012.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

31 May 2023 15:20

RNS Number : 2161B
Hikma Pharmaceuticals Plc
31 May 2023
 

 

Hikma Pharmaceuticals PLC - LTIP and EIP Awards

 

LONDON, 31 May 2023: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2023 Long Term Incentive Plan (the "LTIP"); the 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company. No consideration was paid for the grant of the awards.

Awards under the LTIP were made on 30 May 2023 based on a price of £18.43 per Ordinary Share (being the average mid-market Ordinary Share price for the for the 5-working day period prior to 30 May 2023, in accordance with the LTIP rules) (the "LTIP Awards"). The vesting of the LTIP Awards is subject to the continued employment of the PDMRs, malus and clawback provisions and the satisfaction of performance conditions set by the Remuneration Committee of the Company. The LTIP Awards will normally vest on the later of the third anniversary of the date of grant and the determination of the performance conditions. The LTIP Awards are then subject to an additional two-year holding period.

Awards under the EIP were made on 30 May 2023 based on a price of £15.15 per Ordinary Share (being the average mid-market Ordinary Share price for the 30-day period prior to 31 December 2022, in accordance with the EIP rules) (the "EIP Awards"). All EIP Awards are subject to malus and clawback provisions. EIP Element B Awards will normally vest on the second anniversary of the date of grant, subject to continued employment, and are then subject to an additional three-year holding period. EIP Element C Awards will normally vest on the third anniversary of the date of grant, subject to continued employment, and are then subject to an additional two-year holding period.

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman and Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 132,783 Shares

Nil

EIP Award, Element B: 31,679 Shares

Nil

EIP Award, Element C: 19,761 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 184,223

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 105,233 Shares

Nil

EIP Award, Element B: 36,171 Shares

Nil

EIP Award, Element C: 20,650 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 162,054

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 76,130 Shares

Nil

EIP Award, Element B: 28,647 Shares

Nil

EIP Award, Element C: 20,982 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 125,759

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 74,699 Shares

Nil

EIP Award, Element B: 28,833 Shares

Nil

EIP Award, Element C: 22,209 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 125,741

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 75,339 Shares

Nil

EIP Award, Element B: 36,371 Shares

Nil

EIP Award, Element C: 30,749 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 142,459

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 50,301 Shares

Nil

EIP Award, Element B: 18,836 Shares

Nil

EIP Award, Element C: 13,796 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 82,933

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 38,409 Shares

Nil

EIP Award, Element B: 15,925 Shares

Nil

EIP Award, Element C: 11,664 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 65,998

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Brian Hoffmann

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Brian Hoffmann

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 54,422 Shares

Nil

EIP Award, Element B: 12,233 Shares

Nil

EIP Award, Element C: 8,302 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 74,957

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

Hussein Arkhagha

 1

 Details of the person discharging managerial responsibilities / person closely associated

 a)

 Name

 Hussein Arkhagha

 2

 Reason for the notification

 a)

 Position/status

 PDMR

 b)

Initial notification /Amendment

 Initial notification

 3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 a)

 Name

 Hikma Pharmaceuticals PLC

 b)

 LEI

 549300BNS685UXH4JI75

 4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 a)

Description of the financial instrument, type of instrument and identification code

 Description: Ordinary shares of 10 pence each (Shares)

 ID Code: GB00B0LCW083

 b)

Nature of the transaction

 

Grant of awards under the LTIP and EIP.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

LTIP Award: 41,408 Shares

Nil

EIP Award, Element B: 15,983 Shares

Nil

EIP Award, Element C: 12,406 Shares

d)

Aggregated information

Price(s): nil

Volume(s): 69,797

e)

Date of the transaction

30 May 2023

f)

Place of the transaction

Outside a trading venue

 

 

Helen Middlemist

Deputy Company Secretary+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDUCBXDGXB
Date   Source Headline
1st Jun 201811:34 amRNSTotal Voting Rights
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding
17th May 20181:10 pmRNSDirector/PDMR Shareholding
15th May 20182:26 pmRNSDirector/PDMR Shareholding
3rd May 20189:00 amRNSHikma launches Methotrexate Injection
1st May 20181:38 pmRNSTotal Voting Rights
26th Apr 20181:40 pmRNSHolding(s) in Company
25th Apr 201810:41 amRNSBlock listing Interim Review
24th Apr 20189:00 amRNSHikma expands licensing agreement with Rovi
20th Apr 20189:00 amRNSHikma launches Dexrazoxane for Injection
19th Apr 201812:00 pmRNSAnnual Financial Report and Notice of AGM
10th Apr 20182:34 pmRNSDirector/PDMR Shareholding
3rd Apr 201811:19 amRNSTotal Voting Rights
29th Mar 20189:00 amRNSHikma launch-Palonosetron Hydrochloride Injection
20th Mar 20189:00 amRNSHikma has launched Ritonavir Tablets USP
19th Mar 20183:50 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSFinal Results
12th Mar 20187:00 amRNSUpdate status on ANDA for generic Advair Diskus®
9th Mar 20189:21 amRNSBlock Listing Application
27th Feb 201812:23 pmRNSNotice of Results
20th Feb 20187:00 amRNSSigurdur Olafsson appointed CEO of Hikma
13th Feb 20184:43 pmRNSHolding(s) in Company
8th Feb 201812:41 pmRNSDirector/PDMR Shareholding
8th Feb 201812:39 pmRNSDirector/PDMR Shareholding
8th Feb 201812:37 pmRNSDirector/PDMR Shareholding
26th Jan 20184:56 pmRNSHolding(s) in Company
17th Jan 20185:22 pmRNSHolding(s) in Company
15th Jan 20188:00 amRNSHikma Appoints Dr. Surendera Tyagi
4th Jan 201811:19 amRNSTotal Voting Rights
19th Dec 20179:00 amRNSHikma reaches licensing agreement with Celltrion
13th Dec 20179:00 amRNSHikma- Dihydroergotamine Mesylate Injection, USP
12th Dec 20179:59 amRNSHolding(s) in Company
11th Dec 20179:33 amRNSHolding(s) in Company
1st Dec 20179:28 amRNSTotal Voting Rights
30th Nov 20175:47 pmRNSHikma Ventures- $20.5m Series C round for Prognos
28th Nov 201710:24 amRNSAnnouncement
27th Nov 20171:38 pmRNSHikma Ventures invests in Biolinq
22nd Nov 20179:32 amRNSHolding(s) in Company
20th Nov 20179:32 amRNSHolding(s) in Company
14th Nov 20178:47 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSHikma Acquires Products from Boehringer Ingelheim
8th Nov 20174:45 pmRNSHolding(s) in Company
2nd Nov 20172:51 pmRNSHolding(s) in Company
1st Nov 201711:43 amRNSTotal Voting Rights
30th Oct 20179:26 amRNSHikma launches Pantoprazole Sodium for Injection

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.